Key facts
- Medi2data’s last known valuation is $23.6M (May 2024).
- It has raised $10.1M; the latest was Later Stage VC ($910K) in Mar 2025.
- Notable investors include Innovate UK, Diamond Blade Warehouse, Greyfriars Investments, PricewaterhouseCoopers, Symvan Capital — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Medi2data
- ·The full record, as it builds
Funding rounds
No funding rounds for Medi2data are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Medi2data
Developer of a medical data platform designed to provide fast, consent-driven access to patient medical information. The company offers integration with NHS GP clinical operating systems, proprietary technology, and AI-enabled processes to produce structured and consented medical reports, enabling insurers, government agencies, clinical research organizations, retail health providers, and private medical organizations to access timely and reliable medical data for decision-making and care delivery.
- Sector
- Healthcare
- HQ
- Cardiff, United Kingdom
- Founded
- 2015
- Employees
- 53
- Website
- medi2data.com/
- Ownership
- Privately Held (backing)
Medi2data doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Medi2data shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Medi2data in its N-PORT filings yet. We sweep new filings monthly.